Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Responsevaluatie bij posttransplantatielymfomen door middel van F-FDG-PET/CT en circulerend tumor-DNA (MRD-PTLD)
Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
Published in: Scientific Reports
Access to document
10.1038/s41598-019-47453-5
document
Semiquantitative 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) parameters have been proposed as prognostic markers in classical Hodgkin lymphoma (cHL). In non-Hodgkin lymphoma necrosis as assessed by 18F-FDG PET or computed tomography (CT) (necrosisvisual) correlates with an adverse prognosis. We investigated whether semiquantitative 18F-FDG PET metrics correlate with necrosisvisual, determined the incidence of necrosisvisual and explored the prognostic impact of these factors in cHL. From 87 cHL cases treated with ABVD, (escalated) BEACOPP or CHOP chemotherapy between 2010 and 2017, 71 had both a NEDPAS/EARL accredited 18F-FDG PET and...
X U Kahle, F M Montes de Jesus, T C Kwee, T van Meerten, A Diepstra, S Rosati, A W J M Glaudemans, W Noordzij, W J Plattel, M Nijland
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Published in: Haematologica
Access to document
10.3324/haematol.2018.196899
document
Anton Hagenbeek, Hans Mooij, Josée Zijlstra, Pieternella Lugtenburg, Gustaaf van Imhoff, Marcel Nijland, Sanne Tonino, Martin Hutchings, Marjolein Spiering, Roberto Liu, Harm van Tinteren, Marie José Kersten
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
Published in: Lancet Oncology
Access to document
10.1016/S1470-2045(18)30747-2
Background The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary...
Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Harry C. Schouten, Wendy B. C. Stevens, Josee M. Zijlstra, Joke W. Baars, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martini van den Bent, Max Beijert, Michael Gonzales, Daphne de Jong, Jeanette K. Doorduijn
Characteristics of aggressive B-cell lymphoma
Access to document
10.33612/diss.97523846
document
Aggressive B-cell lymphomas are a heterogeneous group of mature B-cell neoplasms with morphological similarities, but phenotypic and genetic differences. This thesis investigated the aggressive lymphomas from bench-to-bedside aiming to enhance insight into its pathobiology, to investigate mechanisms underlying therapy resistance, and to explore novel treatment combinations. We focused on the role of MYC gene rearrangements, impact of DNA mutations, and altered protein expression. We observed that MYC rearrangements functioned as drivers of transformation in one third of cases in transformed follicular lymphoma. Next, we described loss of human...